The Impact of Focused Ultrasound Thalamotomy of the Anterior Nucleus for Focal-Onset Epilepsy on Anxiety

March 19, 2025 updated by: Timothy Lucas, Ohio State University

.An Open-label Clinical Trial Evaluating the ExAblate Model 4000 Type-1 Focused Ultrasound Unilateral Thalamotomy for Patients with Treatment-refractory Focal Onset Epilepsy and Comorbid Anxiety.

The purpose of this study is to evaluate the feasibility, safety, and effects on anxiety of high intensity focused ultrasound ablation (FUSA) in patients suffering from treatment-refractory focal epilepsy and anxiety. FUSA is a non-invasive neurosurgical procedure that uses ultrasound waves, sent directly through the scalp and skull, to precisely target small abnormal areas of the brain. For this study, the targeted area of the brain is the anterior nucleus of the thalamus. This brain region may cause seizures and may also be involved in anxiety. The study will test if FUSA is safe and tolerated, and if it reduces anxiety and brain response to threat in patients with anxiety receiving the procedure for partial-onset epilepsy that is resistant to medications.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

This is an open-label, Phase 1 prospective intervention study. Ten (10) adults with refractory, partial-onset epilepsy with moderate-severe anxiety and able to provide informed consent will be enrolled.

Patients, eligible for Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN) for treatment-refractory epilepsy and who present moderate-severe anxiety will be enrolled. In addition to the diagnosis of medically refractory epilepsy, patients will need to present moderate to severe anxiety (as measured by the Hamilton Anxiety Rating Scale, HAM-A; HAMA score > 17) and other protocol specific inclusion and exclusion criteria.

Medication-refractory partial or focal-onset epilepsy is often associated with enhanced fear behaviors and clinical anxiety. Exaggerated amygdala reactivity to threat is a cardinal neural phenotype of fear and anxiety disorders. The study will determine if MRgFUSA-ATN is feasible and safe and its effects on anxiety, using neuroimaging and neurological, neurocognitive/neuropsychological, psychiatric assessments before, and 1 day, 1 week, 1 month, 3 months, 6 months and 12 months post MRgFUSA.

Feasibility is defined as the ability to create the desired lesion within the anterior nucleus of the thalamus and perform fMRI to measure threat reactivity.

Safety will be measured by recording and analyzing any adverse effects that may occur from before surgery through 12 months following the surgery. These will include any new onset of neurological deficits, or performance deterioration on neuropsychological testing.

Effects on anxiety will be measured using amygdala reactivity to threat by fMRI and patient- and clinician-reported measures of anxiety symptoms before and after MRgFUSA-ATN up to 12 months.

Study Type

Interventional

Enrollment (Estimated)

10

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Disabling, medically refractory epilepsy (≥2 anti-epileptic drug failures).
  • Focal onset seizures with secondary generalization; with or without primary generalized seizures.
  • Previous seizure work-up within 12 months of enrollment date to include:

A. Home EEG or EMU video EEG or intracranial EEG. B. High definition MRI imaging/PET imaging. C. Baseline neuropsychological assessment, which includes the Wechsler Advanced Clinical Solutions - Test of Premorbid Functioning (TOPF).

  • ≥ 3 seizures/month on average within 3 months of enrollment.
  • Stable medication (including anti-epileptic and psychotropic/psychoactive medications) dosage for 3 months before enrollment.
  • Moderate-severe anxiety as measured by the Hamilton Anxiety Rating Scale (HAM-A) score > 17.
  • Anterior Nucleus (AN) identifiable on MRI (structural T1 and T2 images).
  • Willing to maintain seizure diary (3 months before & 3 months after).
  • Involved care provider.
  • Written informed consent to participate.
  • Ability to comply with all testing, follow-ups, and study appointments and protocols.

Exclusion Criteria:

  • Low seizure frequency (<3 seizures/month).
  • Generalized epilepsy (Lennox Gastaut, drop attacks).
  • Post infectious epilepsy (post herpetic).
  • Unable or unwilling to maintain anti-epilepsy drug dosage for 3 months post treatment.
  • Active (current in past 12 months), uncontrolled DSM-5 psychiatric disorder, except for anxiety disorders.
  • Recent (past 12 months) history of drugs or alcohol abuse as evidenced by diagnosis of Substance Use Disorder.
  • Active suicidal ideation current and past 30 days.
  • Clinically significant neurological disorder, except for epilepsy.
  • Presence of any neurodegenerative disease suspected on neurological examination. These include but are not limited to: Multisystem atrophy; Progressive supranuclear palsy; Dementia with Lewy bodies; Alzheimer's disease; Parkinson's disease.
  • Cerebrovascular disease (multiple CVA or CVA within six months).
  • Significant structural brain abnormalities.
  • Surgical lesion identifiable on imaging.
  • Symptoms and signs of increased intracranial pressure.
  • Patients with any types of brain tumors, including metastases.
  • Previous vagal nerve stimulator.
  • Previous corpus callosotomy.
  • Patients who have had deep brain stimulation.
  • Prior stereotactic ablation.
  • Positive urine drug screen at study entry or any follow-up testing session. For cannabis, exclusion includes positive drug screen with self-report of cannabis use in the past 48 hours.
  • Known allergic reaction and/or hypersensitivity to IV dye and/or IV contrasting agent(s).
  • Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
  • History of claustrophobia.
  • Unstable cardiac status including: Unstable angina pectoris on medication; documented myocardial infarction within last 40 days to protocol entry; Congestive heart failure; Severe hypertension (diastolic BP> 100 on medication).
  • Patients receiving dialysis;
  • Patients with risk factors for intraoperative or postoperative bleeding: Platelet count less than 100,000 per cubic millimeter; PT> 14PTT > 40; INR > 1.43.
  • History of abnormal bleeding and/or coagulopathy.
  • Receiving anticoagulant (e.g., Warfarin) or antiplatelet (e.g., aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk of hemorrhage (e.g., Avastin) within one month of scheduled focused ultrasound procedure.
  • History of intracranial hemorrhage.
  • Active or suspected, acute or chronic uncontrolled infection or known life-threatening systemic disease;
  • History of immunocompromised status, including patients who are HIV positive.
  • Subjects with remarkable atrophy and poor healing capacity of the scalp.
  • Evidence for calcifications that might interfere with treatment safety (per CT).
  • Skull Density Ratio (SDR) <0.4.
  • Pregnancy or lactation or planning to become pregnant during the time-period of the study.
  • Any illness that in the investigators' opinion preclude participation in this study.
  • Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment (can be up to 4 hrs of total table time);
  • IQ score of <70 on the Wechsler Advanced Clinical Solutions - Test of Premorbid Functioning (TOPF), measured as part of screening neuropsychological assessment.
  • Presence of significant cognitive impairment as determined with a score ≤24 on the Mini Mental Status Examination (MMSE).
  • Patients unable to communicate with the investigator and staff.
  • Legal incapacity or limited legal capacity.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention
Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)
Device: Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)
Unilateral Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA) of the anterior nucleus of the thalamus (ATN)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of Treatment-Emergent Adverse Events
Time Frame: 12 months
Safety will be determined by an evaluation of the incidence and severity of MRgFUSA-ATN and other research procedures related adverse events from the 1st study visit through the 12-month post-treatment time point. Post-procedural imaging will be evaluated for evidence of swelling, hemorrhage, and the evolution of the ATN lesion. Emergence of complications will be monitored by neurological examination at day 1, day 7, month 1, month 3, month 6 and month 12 post-procedure. A comprehensive battery of neuropsychological assessments will be conducted by board-certified neuropsychologists at study screening, 3-month and 12-month postoperative time points. All events that are not procedure related will also be captured and recorded.
12 months
Target
Time Frame: 1 month
Feasibility will be determined by ability to create the desired lesion within the anterior nucleus of the thalamus as assessed by neuroimaging
1 month
Change in Anxiety symptoms
Time Frame: 12 months

Change in anxiety symptoms will be measured using clinician-administered HAM-A scale before the procedure and at various time points after the procedure.

HAM-A is the scale of reference used in clinical trials to rate the severity of symptoms of anxiety in patients. It will be collected before and after the procedure at day 1, 7, months 1, 3, 6 and 12 to determine any effect and its change overtime.
12 months
Effect on Threat Reactivity
Time Frame: 1 day
Change in Threat reactivity measured by fMRI task just before and after MRgFUSA
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in seizure frequency
Time Frame: 12 months
Change in seizure frequency between before the procedure and after will be assessed by online or hard copy seizure diary
12 months
Ability to perform the threat reactivity fMRI task just before and after MRgFUSA
Time Frame: 4 years
Ability to perform the fMRI task before and after MRgFUSA will be assessed by recording any delay or inability to perform the assessment
4 years
Change in self-reported anxiety symptoms
Time Frame: 12 months
Change in Self-report symptoms of anxiety using the Beck Anxiety Inventory from before the procedure up to 12 months post-procedure.
12 months
Change in self-reported anxiety symptoms
Time Frame: 12 months
Change in Self-report symptoms on the Anxiety, Depression, Stress scale from before the procedure up to 12 months post-procedure
12 months
Change in quality of life
Time Frame: 12 months
Change in quality of life between before and after the procedure will be measured using the Quality of Life in Epilepsy Inventory before and up to 12 months after the procedure
12 months
Rate of Patient Accrual
Time Frame: 4 years
Feasibility will be assessed by measuring the rate of patient accrual over the 4 years of the study
4 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Ohio State University

Investigators

  • Principal Investigator: Kinh Luan Phan, MD, Ohio State University
  • Principal Investigator: Timothy Lucas, MD, Ohio State University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 4, 2024

Primary Completion (Estimated)

December 1, 2025

Study Completion (Estimated)

December 1, 2025

Study Registration Dates

First Submitted

August 21, 2021

First Submitted That Met QC Criteria

August 26, 2021

First Posted (Actual)

September 2, 2021

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

March 19, 2025

Last Verified

July 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2023H0325

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data will be shared via the NIMH Data Archive, in compliance with NIH policy

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anxiety

Clinical Trials on Magnetic Resonance Imaging-guided Focused Ultrasound Ablation (MRgFUSA)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe